Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: Adjuvant 5-FU/cisplatin and chemoradiation with capecitabine

Table 1 Characteristics of patients (n=31)

Characteristics	Number of (%) patients
Age (yr)
Median	51.9
Range	24-70
Sex
Male	21 (67.8)
Female	10 (32.2)
Type of operation
Radical subtotal gastrectomy	16 (51.6)
Radical total gastrectomy	15(48.4)
Location
Antrum	17 (54.8)
Corpus	9 (29.0)
Cardia	5 (16.1)
Lauren classification
Diffuse	20 (64.5)
Intestinal	6 (19.4)
Mixed	5 (16.1)
Borrmann type
I	1 (3.2)
II	4 (12.9)
III	18 (58.1)
IV	8 (25.8)
Stage
IIIA	11 (35.5)
T2bN2	2 (6.5)
T3N1	9 (29.0)
IIIB	14 (45.2)
T3N2	14 (45.2)
IV (M0)	6 (19.4)
T4N2	1 (3.2)
T2bN3	1 (3.2)
T3N3	4 (13.0)
Number of positive nodes
Median	9
Range	1-49

Table 2 Reasons for the cessation of chemoradiotherapy (n=8)

Reasons for cessation	Number of patients (%)
Protocol treatment completed	23 (74.2)
Toxic effects	6 (19.3)
during chemoradiotherapy	2 (6.4)
during maintenance chemotherapy	4 (12.9)
Patients declined further chemotherapy	2 (6.4)

Table 3 Major toxic effects¹ of chemoradiotherapy

Type of toxic effects	Number of patients (%)
Hematologic anemia	4 (12.9)
Neutropenia	15 (50.2)
Thrombocytopenia	1 (3.2)
Nausea/Vomiting	1 (3.2)
Diarrhea	1 (3.2)
Adhesive ileus requiring operation	2 (6.4)

¹ Major toxic effects were defined as those of grade 3/4.

Table 4 Sites of relapse (n=8)¹

Site	Number of patients with relapse (%)
Locoregional2	3 (9.7)
Peritoneal3	2 (6.4)
Distant4	3 (9.7)

¹Patients relapsed at multiple sites, the total number of relapsed sites was greater than the number of relapsed patients (n=4).

² Tumor detected within the radiation fields.

³ Tumor detected in the peritoneal cavity.

⁴ Metastases were outside the peritoneal cavity (including liver).